Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer.

Brown MS, Kim GHJ, Chu GH, Ramakrishna B, Allen-Auerbach M, Fischer CP, Levine B, Gupta PK, Schiepers CW, Goldin JG.

J Med Imaging (Bellingham). 2018 Jan;5(1):011017. doi: 10.1117/1.JMI.5.1.011017. Epub 2018 Jan 11.

PMID:
29340285
2.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4.

3.

Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway.

Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K.

J Nucl Med. 2017 Mar;58(3):374-378. doi: 10.2967/jnumed.116.182394. Epub 2016 Nov 3.

4.

The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.

Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K.

Nucl Med Commun. 2016 Dec;37(12):1290-1296.

5.

Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis.

Tung R, Bauer B, Schelbert H, Lynch JP 3rd, Auerbach M, Gupta P, Schiepers C, Chan S, Ferris J, Barrio M, Ajijola O, Bradfield J, Shivkumar K.

Heart Rhythm. 2015 Dec;12(12):2488-98. doi: 10.1016/j.hrthm.2015.08.014. Epub 2015 Aug 10.

6.

Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.

Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M.

J Nucl Med. 2015 Mar;56(3):410-6. doi: 10.2967/jnumed.114.151647. Epub 2015 Feb 19.

7.

Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.

Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS.

J Nucl Med. 2015 Jan;56(1):70-5. doi: 10.2967/jnumed.114.148247. Epub 2014 Dec 11.

8.

¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.

Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1199-209. doi: 10.1007/s00259-013-2678-2. Epub 2014 Mar 7.

9.

Dynamic PET/CT with 11C-acetate in prostate cancer.

Schiepers C, Huang SC, Dahlbom M.

J Nucl Med. 2013 Feb;54(2):326. doi: 10.2967/jnumed.112.112532. Epub 2012 Dec 21. No abstract available.

10.

Brain tumors.

Herholz K, Langen KJ, Schiepers C, Mountz JM.

Semin Nucl Med. 2012 Nov;42(6):356-70. doi: 10.1053/j.semnuclmed.2012.06.001. Review.

11.

Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases.

Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR.

Bone. 2012 Jan;50(1):128-39. doi: 10.1016/j.bone.2011.09.053. Epub 2011 Oct 6. Review.

PMID:
22001678
12.

Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.

Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC.

Clin Cancer Res. 2011 Oct 15;17(20):6553-62. doi: 10.1158/1078-0432.CCR-10-3290. Epub 2011 Aug 25.

13.

Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.

Schiepers C, Dahlbom M.

Eur Radiol. 2011 Mar;21(3):548-54. doi: 10.1007/s00330-010-2033-y. Epub 2010 Dec 21.

14.

Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.

Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):711-21. doi: 10.1007/s00259-010-1666-z. Epub 2010 Dec 3.

15.

Molecular mechanisms of bone 18F-NaF deposition.

Czernin J, Satyamurthy N, Schiepers C.

J Nucl Med. 2010 Dec;51(12):1826-9. doi: 10.2967/jnumed.110.077933. Epub 2010 Nov 15. Review.

16.

Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.

Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W.

J Nucl Med. 2010 Oct;51(10):1532-8. doi: 10.2967/jnumed.110.078592. Epub 2010 Sep 16.

17.

Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.

Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC.

J Nucl Med. 2010 May;51(5):720-7. doi: 10.2967/jnumed.109.068361. Epub 2010 Apr 15.

18.

Development and intra-institutional and inter-institutional validation of a comprehensive new hepatobiliary software: Part 1--Liver and gallbladder function.

Krishnamurthy GT, Krishnamurthy S, Gambhir SS, Rodrigues C, Rosenberg J, Schiepers C, Buxton-Thomas M.

Nucl Med Commun. 2009 Dec;30(12):934-44. doi: 10.1097/MNM.0b013e32832ed34a.

PMID:
19858769
19.

A child who refuses to ambulate.

Bucchinder D, Shabani-Rad MT, Schiepers C, Moore T.

Clin Pediatr (Phila). 2009 May;48(4):452-5. doi: 10.1177/0009922808327324. Epub 2008 Nov 17. No abstract available.

PMID:
19015281
20.

1-11C-acetate kinetics of prostate cancer.

Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, Dahlbom M.

J Nucl Med. 2008 Feb;49(2):206-15. doi: 10.2967/jnumed.107.044453. Epub 2008 Jan 16.

21.

18F-FDOPA kinetics in brain tumors.

Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC.

J Nucl Med. 2007 Oct;48(10):1651-61. Epub 2007 Sep 14.

22.

18F-fluorothymidine kinetics of malignant brain tumors.

Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC.

Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1003-11. Epub 2007 Feb 13.

PMID:
17295039
23.

Accuracy of PET/CT in characterization of solitary pulmonary lesions.

Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C.

J Nucl Med. 2007 Feb;48(2):214-20.

24.

18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T.

J Nucl Med. 2006 Jun;47(6):904-11.

25.

Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.

Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA.

Chest. 2006 Feb;129(2):393-401.

PMID:
16478857
26.

Evaluation of metastatic meningioma with 2-deoxy-2-[18F]fluoro-D-glucose PET/CT.

Ghodsian M, Obrzut SL, Hyde CC, Watts WJ, Schiepers C.

Clin Nucl Med. 2005 Nov;30(11):717-20.

PMID:
16237292
27.

Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion.

Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, Czernin J.

Chest. 2005 Oct;128(4):2289-97.

PMID:
16236886
28.

Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.

Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, Silverman DH, Ratib O, Czernin J.

J Nucl Med. 2005 Apr;46(4):603-7.

29.

Positron emission tomography: a coming of age?

Schiepers C.

Eur J Intern Med. 2004 Jun;15(3):143-146. No abstract available.

PMID:
15245714
30.

Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability.

Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, Ratib O, Czernin J.

J Nucl Med. 2004 May;45(5):797-801.

31.

Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images.

Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, Ratib O, Czernin J.

J Nucl Med. 2004 Feb;45(2):290-3.

32.

PET/CT in Colorectal Cancer.

Schiepers C.

J Nucl Med. 2003 Nov;44(11):1804-5. No abstract available.

33.

The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective.

Wong C, Silverman DH, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, Phelps ME, Rao J, Valk P, Czernin J.

Mol Imaging Biol. 2002 Mar;4(2):185-90.

PMID:
14537142
34.

Relationship between 18F-FDG uptake and breast density in women with normal breast tissue.

Vranjesevic D, Schiepers C, Silverman DH, Quon A, Villalpando J, Dahlbom M, Phelps ME, Czernin J.

J Nucl Med. 2003 Aug;44(8):1238-42.

35.

PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.

Schiepers C, Filmont JE, Czernin J.

Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S82-8. Epub 2003 Apr 26. Review.

PMID:
12719922
36.

FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma?

Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J.

Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1166-73. Epub 2002 Jun 4.

PMID:
12192561
37.

The impact of PET on the management of lung cancer: the referring physician's perspective.

Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, Gambhir SS, Rao J, Valk PE, Czernin J.

J Nucl Med. 2002 Jun;43(6):752-6.

38.

Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective.

Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, Valk PE, Czernin J.

J Nucl Med. 2001 Sep;42(9):1334-7.

39.

Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective.

Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, Phelps ME, Valk P, Czernin J.

J Nucl Med. 2001 Apr;42(4):586-90.

40.

Surgical correction of vesicoureteral reflux: 5-year follow-up with 99Tcm-DMSA scintigraphy.

Schiepers C, Mesotten L, Proesmans W, Vereecken R, Verbruggen A, de Roo M.

Nucl Med Commun. 2001 Feb;22(2):217-24.

PMID:
11258409
41.

Decision analysis for the cost-effective management of recurrent colorectal cancer.

Park KC, Schwimmer J, Shepherd JE, Phelps ME, Czernin JR, Schiepers C, Gambhir SS.

Ann Surg. 2001 Mar;233(3):310-9.

42.

The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma.

Schiepers C, Haustermans K, Geboes K, Filez L, Bormans G, Penninckx F.

Cancer. 1999 Feb 15;85(4):803-11.

PMID:
10091757
43.

18-FDG imaging in breast cancer.

Hoh CK, Schiepers C.

Semin Nucl Med. 1999 Jan;29(1):49-56. Review.

PMID:
9990683
44.

Measurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosis.

Schiepers C, Broos P, Miserez M, Bormans G, De Roo M.

Arch Orthop Trauma Surg. 1998;118(3):131-5.

PMID:
9932186
45.

Positron emission tomography as a diagnostic tool in oncology.

Schiepers C, Hoh CK.

Eur Radiol. 1998;8(8):1481-94. Review.

PMID:
9853241
46.

Three-phase bone scan and dynamic vascular scintigraphy in algoneurodystrophy of the upper extremity.

Schiepers C, Bormans I, De Roo M.

Acta Orthop Belg. 1998 Sep;64(3):322-7.

PMID:
9828481
47.

Evaluating tumor biology and oncological disease with positron-emission tomography.

Silverman DH, Hoh CK, Seltzer MA, Schiepers C, Cuan GS, Gambhir SS, Zheng L, Czernin J, Phelps ME.

Semin Radiat Oncol. 1998 Jul;8(3):183-96. Review.

PMID:
9634495
48.

Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET.

Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, De Roo M.

J Nucl Med. 1997 Dec;38(12):1970-6.

49.

Development and evaluation of a kit formulation for the preparation of 99mTc-DMP-HSA, a new tracer agent for radionuclide ventriculography.

Verbeke KA, Schiepers CW, Wyndaele DN, Baetens JA, Verbeke GN, De Roo MJ, Verbruggen AM.

Nucl Med Biol. 1997 Aug;24(6):571-8.

PMID:
9316087

Supplemental Content

Loading ...
Support Center